Treatment of Acute and Chronic Wound in Immunodeficiency Patients Using Easyef(R) (EGF).
- Author:
Jae Hyun CHO
1
;
Dae Hyun LEW
;
Yu Seun KIM
;
Kwan Chul TARK
Author Information
1. Department of Plastic & Reconstructive Surgery and Institute for Human Tissue Restoration, Yonsei University College of Medicine, Seoul, Korea. dhlew@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Growth factor;
Wound healing;
Immunodeficiency patient
- MeSH:
Cicatrix;
Epidermal Growth Factor;
Humans;
Immunity, Humoral;
Inflammation;
Intercellular Signaling Peptides and Proteins;
Skin;
Wound Healing;
Wounds and Injuries*
- From:The Journal of the Korean Society for Transplantation
2006;20(1):99-103
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The mechanism of wound healing is a complex process which includes coagulation, inflammation, fibroplasia and scar remodeling phase. Various factors, such as immune status of host, growth factors and many enzymes play significant roles in wound healing process. Especially those who are immunosuppressed have reduced humoral immunity leading to blockade in inflammatory phase and decreased secrection of various growth factors, resulting in delayed wound healing. We tried to accelerate the wound healing process in the immunosuppressed patients by introducing the exogenous growth factors. METHODS AND RESULTS: From March 2004 to February 2005, ten patients who were administered with immunosuppressant medications or had undergone long-term immuno-deficit state were treated with EGF. Patients had an average of 9 x 6 cm skin defect due to either trauma or infection, and with good wound care and twice-a-day application of Easyef(R)(human recombinant epidermal growth factor, Dae-Woong), complete healing was achieved in all wounds in an average of 3 months. CONCLUSION: The treatment of wound with application of epidermal growth factor can be a method of choice in treating wounds in the immunosuppressed patients.
